Krt-232, A First-In-Class, Murine Double Minute 2 Inhibitor (Mdm2i), For Tp53 Wild-Type (P53(Wt)) Merkel Cell Carcinoma (Mcc) After Anti-Pd-1/L1 Immunotherapy.

Michael K.K. Wong,Ciara Marie Kelly,Melissa Amber Burgess,Karl Lewis,Jaspreet Singh Grewal,Anthony J. Olszanski,Jesse McGreivy,Wayne Rothbaum,Hope Qamoos,James A. DeCaprio

JOURNAL OF CLINICAL ONCOLOGY（2020）

Cited 9|Views4

No score

Abstract

10072Background: MCC is an aggressive neuroendocrine skin cancer with very poor prognosis. Immune checkpoint inhibition was recently shown to benefit some patients (pts). There are few effective tr...

Translated text

Key words

merkel cell carcinoma,tp53,anti–pd-1/l1 immunotherapy,first-in-class,wild-type

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined